Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue: +58.1%
EPS: +142.2%
Free cash flow: +43.5%

Quarter to September 2026, against a year earlier

88.50 7.62 −7.93%

Follow KNSA

Alert me

Market cap: $6.9B
P/E: 62.1×
Fwd P/E: 67.8×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Pharmaceutical	678	100.00%
Gross margin		88.54%
Operating margin		11.40%
Pre-tax margin		13.12%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Product revenue, net	678 100.00%	417 98.53%	233 86.28%	123 55.65%	39 100.00%
License and collaboration revenue	—	6 1.47%	37 13.72%	98 44.35%	—
Revenue	678	423	270	220	39

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021
License and collaboration revenue	‡	‡	‡	‡	‡
Product revenue, net	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023
Pharmaceutical	678 100.00%	423 100.00%	270 100.00%
Revenue	678	423	270

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Average total duration of ARCALYST therapy in recurrent pericarditis	Q3 FY2026	3.00	32.00	−90.62%
Prescribers who have written ARCALYST prescriptions for recurrent pericarditis	Q3 FY2026	5.5K	—	—
Target multiple-recurrence patients actively on ARCALYST treatment	Q3 FY2026	23.0%	—	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024
Average total duration of ARCALYST therapy in recurrent pericarditis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Prescribers who have written ARCALYST prescriptions for recurrent pericarditis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Target multiple-recurrence patients actively on ARCALYST treatment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.